---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-056209"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:43:55.618498+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share

## Summary
- Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.
- Underwriters granted 30-day option to purchase up to 468,750 additional shares at $32.00 less discounts.
- Gross proceeds ~$100M; net proceeds expected ~$93.7M after discounts and expenses.
- Offering expected to close March 5, 2024, subject to customary conditions.
- Goldman Sachs, BofA, Guggenheim, and Oppenheimer are joint book-running managers.

## SEC filing metadata
- accession: 0001193125-24-056209
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/0001193125-24-056209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/d759306d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-056209
- JSON: https://secwatch.observer/filing/0001193125-24-056209.json
- Plain text: https://secwatch.observer/filing/0001193125-24-056209.txt

## Key facts
- Material Agreements
  Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC valued at expected to be approximately $93.7 million (effective 2024-02-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC
  - Value: expected to be approximately $93.7 million
  - Effective: 2024-02-29
  source text: On February 29, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,812,500 shares of the Company’s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/0001193125-24-056209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.